Professor Sara Hurvitz (David Geffen School of Medicine at UCLA, Los Angeles, CA, USA) discusses her presentation at the San Antonio Breast Cancer Symposium 2021 on the aims, efficacy and safety findings of the TRINITI-1 study.
1. What are the major unmet needs in the treatment of women with HR+, HER2− breast cancer? 00:12-02:06
2. What were the aims, efficacy and safety findings of the TRINITI-1 study? 02:06-05:22
3. What will be the clinical impact of these findings? 05:22-06:06
Speaker Disclosure: Sara Hurvitz has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the San Antonio Breast Cancer Symposium 2021
Share this Video
Related Videos In Breast Cancer
Aditya Bardia, SABCS 2021: Results of EMERALD Phase III Trial
Dr Aditya Bardia (Harvard Medical School, Boston, MA, USA) discusses the results of the phase III EMERALD trial, exploring elacestrant, an oral selective estrogen receptor degrader, vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer following progression on prior endocrine and CDK4/6 inhibitor therapy. These results were presented at the San Antonio Breast […]
Nancy Lin, SABCS 2021: Updated Results of the HER2CLIMB Study
Dr Nancy Lin (Dana-Farber Cancer Institute, Boston, MA, USA) discusses the updated results of the phase II HER2CLIMB study, which assessed tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases. These results were presented at the San Antonio Breast Cancer Symposium 2021. Questions 1. […]
Marta Vaz Batista, SABCS 2021: Preliminary Results From the DEBBRAH Phase II Study
Dr Marta Vaz Batista (Hospital Fernando Fonseca, Amadora, Portugal) discusses the preliminary results from the DEBBRAH phase II study, exploring trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement. These results were presented at the San Antonio Breast Cancer Symposium 2021. Questions 1. Could you tell us a […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!